MA-WHOOP
29.4.2024 20:11:30 CEST | Business Wire | Press release
WHOOP, the human performance company, today announced the expansion of its global footprint, now shipping to 56 markets worldwide, with more launches ahead. Additionally, the WHOOP app is now available in Italian and Spanish (Latin America), as well as English, French, and German. To support continued growth and momentum, WHOOP named new leaders to its C-suite to deliver on the WHOOP mission of helping people achieve their goals, by providing best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, strain, and health. To help everyone start their journey, WHOOP is currently offering a one-month free trial that can be accessed on WHOOP.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429085870/en/
WHOOP announces significant global expansion, appoints new senior leadership. Continues "Free Trials," making it the only wearable to offer "Try Before You Buy." (Photo: Business Wire)
WHOOP Global Expansion
With a commitment to serving its global community to unlock their potential, WHOOP has expanded its reach to several key markets and regions, where there’s been rising consumer demand for and adoption of the brand. Consumers in Qatar, Saudi Arabia, Kuwait, Bahrain, Hong Kong, Israel, Korea, and Taiwan can now purchase WHOOP directly and the brand will ship to each of these markets, creating a seamless experience for its members.
The Gulf is a key region for the brand’s growth. In fact, their digital health market is expected to witness healthy, double-digit growth by 2027, according to Medi-Tech Insights. As a world class health and performance monitor, WHOOP provides coaching to improve overall well-being and foster behavior change.
To support global expansion, the WHOOP app is now available in Italian and Latin American Spanish to complement its existing languages: English, French and German, with additional language rollouts to come. This expansion ensures that WHOOP members worldwide can access the full suite of content and features in their native language.
“WHOOP is experiencing remarkable growth and momentum, particularly in new markets around the world. We’re excited to open these new markets and provide over 125 million people with access to WHOOP,” said Will Ahmed, Founder and CEO of WHOOP. “This market growth and the launch of Spanish and Italian in the WHOOP app is just the start of our international expansion. Our teams, including those led by three of our newest C-suite leaders, are working every day to unlock new markets and help introduce new members to the power of our WHOOP membership.”
New Executive Leadership at WHOOP
To spearhead continued growth and global expansion, WHOOP has appointed new leaders to its executive team:
- Ed Baker joins WHOOP as Chief Growth Officer, following the acquisition of Baker's previous company, AnyQuestion. Before that, Baker led growth teams at Facebook and Uber during periods of extraordinary growth. He has also served on the WHOOP Board of Directors for nearly five years. Baker will lead efforts to fuel the next phase of hyper-growth at WHOOP.
- Michener Chandlee is now Chief Financial Officer at WHOOP, leveraging his extensive financial expertise to drive strategic financial planning and operational excellence. Prior to WHOOP, Chandlee was the CFO of Fanatics and also spent nearly 20 years at Nike in various leadership roles, including Chief Risk Officer and CFO of Nike’s Global Marketplace.
- John Sullivan has been promoted to Chief Marketing Officer, bringing his wealth of experience in marketing strategy and brand development to further elevate the presence of WHOOP in the global marketplace. Sullivan has worked at WHOOP for more than seven years during which he’s developed the direct-to-consumer business at WHOOP, overseeing all marketing functions of Brand, Commercial, Lifecycle, Business Development and Accessories and Apparel. Prior to WHOOP, he held positions in marketing at Tracksmith, Puma and Monitor Group, a strategy consulting firm.
To learn more and discover how WHOOP helps its members unlock their performance, go to www.whoop.com. To make it even more convenient than ever before to access WHOOP, it is available for purchase on Amazon.com, as well as at Best Buy and Dick’s Sporting Goods.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429085870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom